156 related articles for article (PubMed ID: 19258410)
1. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
Sherman SI
J Clin Endocrinol Metab; 2009 May; 94(5):1493-9. PubMed ID: 19258410
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of thyroid cancer.
Sherman SI
Biochem Pharmacol; 2010 Sep; 80(5):592-601. PubMed ID: 20471374
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for thyroid tumors.
Sherman SI
Mod Pathol; 2011 Apr; 24 Suppl 2():S44-52. PubMed ID: 21455200
[TBL] [Abstract][Full Text] [Related]
4. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors and the thyroid.
Sherman SI
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
7. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
8. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Aller S; Popescu A; Rao S; Morgan E; Gosiengfiao Y
Pediatr Blood Cancer; 2012 Jan; 58(1):98-100. PubMed ID: 21721105
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
10. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
11. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
12. New directions in the systemic treatment of metastatic thyroid cancer.
Higgins MJ; Forastiere A; Marur S
Oncology (Williston Park); 2009 Aug; 23(9):768-75. PubMed ID: 19777762
[TBL] [Abstract][Full Text] [Related]
13. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
14. An update on clinical trials of targeted therapies in thyroid cancer.
Haraldsdottir S; Shah MH
Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer.
Sherman SI
Oral Oncol; 2013 Jul; 49(7):707-10. PubMed ID: 23582411
[TBL] [Abstract][Full Text] [Related]
17. Update on medullary thyroid cancer.
Hu MI; Ying AK; Jimenez C
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.
Harris PJ; Bible KC
Expert Opin Investig Drugs; 2011 Oct; 20(10):1357-75. PubMed ID: 21910667
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in radioiodine refractory thyroid cancer.
Pacini F; Brilli L; Marchisotta S
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
